Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial
about
Oligometastatic Prostate CancerAntineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cellsEndocrine treatment in prostate cancerPredictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapyEarly versus deferred androgen suppression in the treatment of advanced prostatic cancer.Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyDiagnosis and management of early prostate cancer. Report of a British association of urological surgeons working party.Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects.Angiogenesis inhibitors in the treatment of prostate cancer.Treatment of prostate cancer.Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support.The management of prostate cancer in patients with a rising prostate-specific antigen level.Use of androgen deprivation therapy for metastatic prostate cancer in older men.Prostate cancer screening.Treatment options after failure of local curative treatments in prostate cancer: a controversial issue.Adjuvant chemo-/hormonal therapy trials for locally advanced prostate cancer.Intermittent androgen deprivation.Radical radiation therapy options for organ-confined prostate cancer.Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.New therapeutic concepts in prostate cancer.Endocrine therapy for prostate cancer.The treatment of prostate cancer: an overview of current options.Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.Quality of life following prostate cancer treatments.Follow-up surveillance strategies for genitourinary malignancies.The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma.Controversies surrounding androgen deprivation for prostate cancer.Risk stratification in the hormonal treatment of patients with prostate cancerRadiotherapy for t3 prostate cancer.Improvement in urinary symptoms after radical prostatectomy: a prospective evaluation of flow rates and symptom scores.Metastatic prostate cancer: complications and treatment.Intermittent androgen suppression.Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?Early versus late hormonal therapy for prostate cancer.State-of-the-art approaches to detecting early bone metastasis in prostate cancer.Biochemical failure: role for early hormonal therapy.Hormonal treatment alone for locally advanced prostate cancer.Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.Long-term outcome of detectable PSA levels after radical prostatectomy.
P2860
Q28075182-07A1CA69-1CCC-4087-B028-C2831C8258F9Q28288947-AFC7E737-379D-4616-B6EA-7FBC57E27F26Q28378298-88E2D4C8-3B72-4832-A242-0F114BA39176Q28541955-EE698994-959C-405A-AA4E-AD15EDB4D609Q32064496-F49BDCBD-5AED-48C5-9EBF-A240BE221F0EQ33320071-B8B33849-E16F-4F37-BAAF-F6F7A326AC2AQ33610857-C15154A8-0CB0-4873-8D16-2C212105DA3AQ33610869-2809F4F5-A4D7-412C-9360-9F72EB97F162Q33611121-6182E5D2-7FE6-4537-8D25-5A8FD82BBDEDQ33668839-09B44D0A-58E3-417B-B2A5-7285D0157C16Q33889276-FC1F1860-2352-49FA-BB6E-FDC83BDEF251Q33910607-F27916A8-C6F7-4A39-B9AE-FCC2B051F949Q33962011-F8600EAE-A74D-4C6A-937D-D1A69465A968Q33977514-E590A10E-DCF5-4257-A68E-8CD43C98517FQ34080718-C2E08C41-1FAE-4676-8223-8E5E8FCC942FQ34105531-0882342D-F524-451E-8DBB-BB8323EE9047Q34108014-4A010148-11FF-4D13-9E3F-993295E3F532Q34108020-287A2127-72BE-4421-A2C8-868498E22E1EQ34216136-0CC151A5-B0CD-4B0E-AA2E-D9C12A45BE98Q34310143-F975ADFB-E454-4AD5-9896-0CB851DE8035Q34394082-A5CA549A-840B-49DD-8151-3ABECCC9257DQ34451239-471A108A-225A-4D80-894B-8DE28C909F5AQ34552438-76FDD21E-9678-48CE-8BA6-F6334AF565E3Q34585070-2E212280-5C2A-4A2A-9657-B013F621C235Q34707853-0E574B06-57FA-41BE-9590-517FD68E44D0Q34736606-09F322BE-7C95-4010-ADD2-7BDE8A5FF36CQ34747431-EDE6F1DE-3868-4F35-975A-C45C79BE6920Q34849222-B41BA56D-BA66-4DF2-90E5-F922D6B3AB2DQ35076189-D5AC8456-A40A-4373-8583-92B5CD2BDC0FQ35131048-533593FF-1575-419D-93F7-23B95ADE4032Q35142719-A2EB8955-B68D-4BD9-9C53-6808C221A5F2Q35188493-A49AD1CD-B238-4DFA-8308-2C30332EDBC7Q35649343-749006DF-5CCE-465B-B87A-0BDE8D234E43Q35721083-CB381438-ACBB-4778-8F5F-D1BB2210272FQ35783011-2C47AF2E-F8EB-42A2-BB14-03F7019E1655Q35854984-EEDC3D71-80C2-488E-94FE-19EF4A0C0B10Q35937044-38758879-9C03-4979-8995-F862A5452049Q35937056-0AAB7F93-D611-438C-A72E-97752B3ECCA0Q36023678-888DEE7B-DF14-48C3-9684-B28F80453535Q36042296-116ABFC0-B533-46C8-A9B6-2DDF946A2BC7
P2860
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial
description
scientific article published on 01 February 1997
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1997
@uk
name
Immediate versus deferred trea ...... Medical Research Council trial
@en
Immediate versus deferred trea ...... Medical Research Council trial
@nl
type
label
Immediate versus deferred trea ...... Medical Research Council trial
@en
Immediate versus deferred trea ...... Medical Research Council trial
@nl
prefLabel
Immediate versus deferred trea ...... Medical Research Council trial
@en
Immediate versus deferred trea ...... Medical Research Council trial
@nl
P1476
Immediate versus deferred trea ...... king Party Investigators Group
@en
P304
P356
10.1046/J.1464-410X.1997.D01-6840.X
P577
1997-02-01T00:00:00Z